Pricing of orphan drugs in oncology and rare diseases
Objective: The objective of this paper is to determine an upper price limit for an orphan drug by taken a broader perspective and, including also other monetary and non-monetary values for the society. Methods: This model is based on the expected free cash flows and the required minimum rate of retu...
Saved in:
Main Authors: | Mark Nuijten (Author), Stefano Capri (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of early phase price agreements on prices of orphan drugs
by: Mark Nuijten, et al.
Published: (2021) -
Negotiating Medical Insurance Drug Prices: The Role in Reducing Costs of Orphan Drugs for Rare Diseases
by: Jinmiao Lu, et al.
Published: (2023) -
Pricing Zolgensma - the world's most expensive drug
by: Mark Nuijten
Published: (2022) -
Rare diseases and orphan drugs
by: Domenica Taruscio, et al.
Published: (2011) -
Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023)